. 2021 Sep 18;10(9):2475. doi: 10.3390/cells10092475

Table 2.

The impact of rapamycin-preconditioned ADSCs on liver biochemical parameters; ALT, AST and albumin, after cisplatin (Cis)-induced liver damage.

Group	ALT (U/L)	AST (U/L)	Albumin (g/dL)
Control	48.16 ± 3.06	102 ± 14.71	3.35 ± 0.46
Cis	141.17 ± 8.56 *	268.67 ± 54.7 *	2.21 ± 0.61 *
Cis + ADSCs	104.33 ± 10.17 *^,#	171 ± 71.35 *^,#	2.63 ± 0.61 *^,#
Cis + Rapa-ADSCs	85.83 ± 10.57 *^,#,$	114.67 ± 25.14 ^#,$	3.08 ± 0.39 ^#,$

Cis, cisplatin (i.p. injection of 5 mg/kg in 0.9% saline) group; Cis + ADSCs, cisplatin group receiving ADSCs (one million cells, intravenous in tail vein); Cis + Rapa-ADSCs, cisplatin group receiving same number of ADSCs preconditioned with rapamycin (50 nM/L, 2 h prior to administration); * vs. control group (p < 0.01); ^# vs. Cis group (p < 0.01); ^$ vs. Cis+ADSCs group (p < 0.05).